Canaccord Genuity Group cut their price objective on Evolent Health from $48.00 to $44.00 in a research note on Thursday, November 3rd.

Source: https://www.americanbankingnews.com/2023/02/01/bi-asset-management-fondsmaeglerselskab-a-s-grows-stock-position-in-evolent-health-inc-nyseevh.html

Finally, BTIG Research lowered their price objective on Evolent Health from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, October 12th.

Source: https://www.etfdailynews.com/2023/01/13/allspring-global-investments-holdings-llc-boosts-stock-holdings-in-evolent-health-inc-nyseevh/

Finally, Wedbush reiterated an “outperform” rating on shares of Evolent Health in a research report on Thursday, November 16th.

Source: https://www.dailypolitical.com/2023/12/04/hsbc-holdings-plc-invests-2-67-million-in-evolent-health-inc-nyseevh.html

The following slide deck was published by Evolent Health, Inc. in conjunction with their 2023 Q2 earnings call.

Source: https://seekingalpha.com/article/4623158-evolent-health-inc-2023-q2-results-earnings-call-presentation?source=feed_all_articles